# Ramucirumab Biosimilar, Anti-human VEGFR-2 Antibody | Catalog C061P

Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody. The research grade ramucirumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available.

## Product Specifications

| | |
|---|---|
| **Catalog No.** | C061P |
| **Product Name** | Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody |
| **Supplier Name** | Syd Labs, Inc. |
| **Brand Name** | Syd Labs |
| **Synonyms** | Anti-KDR Human Monoclonal Antibody, Ramucirumab Research Grade, Ramucirumab RUO |
| **Summary** | Recombinant Human IgG1 Monoclonal Antibody. |
| **Source/Host** | Produced in mammalian cells. |
| **Specificity** | Specifically binds to the human VEGFR2 (KDR). |

## Properties & Storage

| | |
|---|---|
| **Applications** | ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ramucirumab. |
| **Formulation** | 0.2 µM filtered solution, pH 6.0, no stabilizers or preservatives. |
| **Endotoxin** | < 1 EU per 1 mg of the protein by the LAL method. |
| **Purity** | >95% by SDS-PAGE under reducing conditions and HPLC. |
| **Shipping** | Shipped with ice pack. Store immediately at recommended temperature. |
| **Storage** | 12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles. |

## Background & Description

Research grade Ramucirumab biosimilar uses the same protein sequences as the therapeutic antibody ramucirumab. Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and blocks the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D).

These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.